Analysis of Revenues
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Cash Flow Statement
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Pfizer Inc., income statement, revenues
US$ in millions
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Revenue Trends Overview
- The overall revenue demonstrates significant volatility over the time period from 2020 to 2024. Following a notable increase from 42,678 million USD in 2020 to a peak of 101,175 million USD in 2022, revenues then decreased sharply in 2023 to 59,553 million USD before showing a slight rebound to 63,627 million USD in 2024.
- Primary Care Segment
- The primary care segment exhibits substantial fluctuations, with revenues increasing dramatically from 15,577 million USD in 2020 to 73,181 million USD in 2022. However, this was followed by a steep decline to 30,799 million USD in 2023 and a slight further decrease to 30,135 million USD in 2024. This pattern suggests a peak in demand or perhaps one-time gains in 2022, not sustained in subsequent years.
- Specialty Care Segment
- Specialty care revenues show modest increases and some variability across the years. Starting at 14,280 million USD in 2020, the segment grows to 15,194 million USD in 2021, then slightly dips to 13,851 million USD in 2022. Revenues rise again to 14,988 million USD in 2023 and reach 16,652 million USD in 2024, indicating a generally stable and slightly upward trend in this segment.
- Oncology Segment
- Oncology revenues display consistent growth from 10,867 million USD in 2020 to 12,333 million USD in 2021, increasing further to 12,794 million USD in 2022. While there is a minor decline to 12,450 million USD in 2023, a substantial increase to 15,612 million USD is observed in 2024, indicating renewed strength and growth potential in the oncology business.
- Global Biopharmaceuticals Business (Biopharma)
- The biopharma segment revenue mirrors overall revenues but on a larger scale due to its aggregation of sub-segments. Revenues surge from 40,724 million USD in 2020 to a peak at 99,826 million USD in 2022, decline to 58,237 million USD in 2023, and slightly recover to 62,399 million USD in 2024. These changes reflect the volatility experienced across primary care and other pharmaceutical areas.
- Pfizer Centreone
- This segment shows a generally declining trend, starting from 1,954 million USD in 2020, rising briefly to 2,589 million USD in 2021, but then decreasing notably over the subsequent years to 1,342 million USD in 2022, 1,272 million USD in 2023, and 1,146 million USD in 2024, suggesting a contraction or reduced performance in this division.
- Pfizer Ignite
- This segment emerges late, with no reported revenue until 2022, when it shows a modest 7 million USD. Revenues increase progressively to 44 million USD in 2023 and 82 million USD in 2024, indicating a growing but still minor contribution within the overall revenue structure.